Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000561703 | SCV000666477 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-08-24 | criteria provided, single submitter | clinical testing | The p.R191G variant (also known as c.571C>G), located in coding exon 7 of the MUTYH gene, results from a C to G substitution at nucleotide position 571. The arginine at codon 191 is replaced by glycine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000705814 | SCV000834830 | uncertain significance | Familial adenomatous polyposis 2 | 2024-07-30 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 191 of the MUTYH protein (p.Arg191Gly). This variant is present in population databases (no rsID available, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with MUTYH-related conditions. ClinVar contains an entry for this variant (Variation ID: 481803). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Color Diagnostics, |
RCV000561703 | SCV002052161 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-03-16 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with glycine at codon 191 of the MUTYH protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/251480 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002476227 | SCV002776082 | uncertain significance | Familial adenomatous polyposis 2; Gastric cancer | 2024-05-06 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000705814 | SCV004198902 | uncertain significance | Familial adenomatous polyposis 2 | 2024-02-09 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478235 | SCV004222093 | uncertain significance | not provided | 2023-10-06 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000705814 | SCV004837301 | uncertain significance | Familial adenomatous polyposis 2 | 2023-04-03 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with glycine at codon 191 of the MUTYH protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 1/251480 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |